LifeSci Acquisition Corporation (LSAC) Shareholders Approve Vincera Deal

LifeSci Acquisition Corporation (NASDAQ:LSAC) announced in an 8-K that its shareholders approved its combination with cancer drug developer Vincera Pharma at a special meeting earlier today.

The parties expect the transaction to close tomorrow, December 23. The filing did not divulge redemption figures, but LifeSci opened the morning of the vote at $19, so one would guess they were “manageable”.

All measures up for a vote passed by wide margins, but about 12.5% of shares voted against the combined company’s incentive plan.

LifeSci initially announced its combination with with Vincera September 29. Vincera is developing a preclinical bioconjugation platform targeting surface markers for solid tumors.

For a full list of measures on the ballot as well as vote tallies, click HERE.